CHMP meets to discuss Avandia, but releases no new information
This article was originally published in Scrip
Executive Summary
The EU's CHMP met on 8 September to discuss an ongoing review of the safety profile of GlaxoSmithKline's troubled diabetes drug Avandia (rosiglitazone). Despite keen anticipation over the outcome of the meeting, the committee has stayed tight-lipped over its view of the drug, which has been linked with cardiovascular safety issues.